Clone Emergence and Evolution in Chronic Lymphocytic Leukemia: Characterization of Clinical, Laboratory and Immunophenotypic Profiles of 25 Patients

References

• Rai K. R., Sawatsky A., Cronkite E. P., Chanana A. D., Levy R. N., Pasternack B. S. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46: 219–234
   PubMed Web of Science ®Google Scholar
• Binet J. L., Catovsky D., Chandra P., Dighiero Montserrat C. E., Rai K. R., Sawitsky A. Chronic lymphocytic leukemia: Proposal for a revised prognostic staging system. Br. J. Haematol. 1981; 48: 365–367
   PubMed Web of Science ®Google Scholar
• Faguet G. B., Agee J. F. Immunophenotypic diagnosis of clinical and preclinical chronic lymphatic leukemia by using monoclonal antibodies against the cCLLa, a CLL-associated antigen. Blood 1988; 72: 679
   PubMed Web of Science ®Google Scholar
• International Workshop on Chronic Lymphocytic Leukemia. Recommendations for Diagnosis, Staging and Response criteria. Annals of Int. Med. 1989; 110: 236
   PubMed Web of Science ®Google Scholar
• Cheson B. D., Bennet J. M., Rai K. R., Grever M. R., Kay N. E., Schiffer C. A., Oken M. M., Keating M. J., Boldt D. H., Kempin S. J., Foon K. A. Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the National Cancer Institute-sponsored Working Group. Am. J. Hemalol 1988; 29: 152
   PubMed Web of Science ®Google Scholar
• Agee J. F., Garver F. A., Faguet G. B. An antigen common to chronic lymphocytic and hairy cell leukemia cells not shared by normal lymphocytes nor by other leukemia cells. Blood 1986; 68: 62
   PubMed Web of Science ®Google Scholar
• Faguet G. B., Agee J. F. Monoclonal antibodies against the chronic lymphatic leukemia antigen, cCLLa: Characterization and reactivity. Blood 1987; 70: 437
   PubMed Web of Science ®Google Scholar
• Faguet G. B., Agee J. F. Modulation, shedding and serum titers of the chronic lymphatic leukemia-associated antigen (cCLLa): Characterization and clinical correlations. Blood 1988; 74: 2493
   Web of Science ®Google Scholar
• Faguet G. B. Common chronic lymphatic leukemia antigen (cCLLa); Distribution, fate and clinical applications. Nouv. Rev. Fr. Hemalol 1988; 30: 305–310
   PubMedGoogle Scholar
• Faguet G. B. Lymphocyte purification, an improved method: Qualitative and quantitative evaluation. Biomedicine 1974; 21: 153–157
   PubMedGoogle Scholar
• Faguet G. B., Satya-Prakash K. L., Agee J. F. Cytochemical, cytogenetic, immunophenotypic and tumori-genic characterization of two hairy cell lines. Blood 1988; 71: 422–429
   PubMed Web of Science ®Google Scholar
• Heinivaara O. Smudged Cells in Lymphocytic Leukemia. Ann, Med, Intern, Fenniae 1959; 48: 69
   PubMedGoogle Scholar
• Kipps T. J. The CD5 B-cells. Adv. Immunol. 1989; 47: 117
   PubMed Web of Science ®Google Scholar
• Sthoeger Z. M., Wakai M., Tse D. B., Vinciguerra V. P., Allen S. L., Budman D. R., Lichtman S. M., Schulman P., Weiselberg L. R., Chiorazzi N. Production of Autoantibodies by CD5-expressing B lymphocytes from patients with chronic lymphocytic leukemia. J. Exp. Med. 1989; 169: 255
   PubMed Web of Science ®Google Scholar
• Borche I., Lim A., Binet J. L., Dighiero G. Evidence that CLL B-lymphocytes are frequently committed for the production of multispecific autoantibodies. Blood 1989; 74: 146A.
   Google Scholar
• Hardy R. R., Hayakawa K., Shimizu M., Yamasaki K., Kishimoto T. Rheumatoid factor secretion from human leu-1 + B cells. Science 1987; 236: 81
   PubMed Web of Science ®Google Scholar
• Dauphinee M., Tovar Z., Talal N. B cells expressing CD5 are increased in Sjogren's syndrome. Arthritis Rheum. 1988; 31: 642
   PubMed Web of Science ®Google Scholar
• Ault K. A., Antin J. H., Ginsgurg D., Orkin S. H., Rappeport J. M., Keohan M. L., Martin P., Smith B. R. Phenotype of recovering lymphoid cell populations after marrow transplantation. J. Exp. Med. 1985; 161: 1483
   PubMed Web of Science ®Google Scholar
• Preud'homme J. L., Seligman M. Surface bound immunoglobulins as a cell marker in human lymphoprolifera-tive diseases. Blood 1974; 3: 853
   Google Scholar
• Aisenberg A. C., Bloch K. L., Long J. C. Cell surface immunoglobulin in chronic lymphocytic leukemia and allied disorders. Am. J. Med. 1973; 55: 184
   PubMed Web of Science ®Google Scholar
• Catovsky D., Cherchi M., Okos A., Hedge U., Galton D. A. Mouse red blood cell rosettes in B lymphoproliferative disorders. Br. J. Haematol 1976; 33: 173
   PubMed Web of Science ®Google Scholar
• Calgaris-Cappio F., Janossy G. Surface markers in chronic lymphoid leukemias of B cell type. Semin. Hemalol 1985; 22: 1
   PubMed Web of Science ®Google Scholar
• Wang C. J., Good R. A., Ammirati P., Dymbort G., Evans R. L. Identification of p69,71 complex expressed on human T cells sharing determinants with B type chronic lymphocytic cells. J Exp. Med. 1980; 151: 1539
   PubMed Web of Science ®Google Scholar
• Royston I., Majda J. A., Baird Mersuve S. M., Griffiths J. C. Human T-cell antigens defined by monoclonal antibodies: The 65,000 dalton antigen to T-cells (T65) is also found on chronic lymphocytic leukemia cells bearing surface immunoglobulins. J. Immunol. 1980; 125: 725–731
   PubMed Web of Science ®Google Scholar
• Faguet G. B., Agee J. F., Marti G. E. CD5 and cCLLa expression by chronic lymphocytic leukemia (CLL) cells: Demonstration of the relative prevalence of these B-CLL markers. Leukemia & Lymphoma. 1990, in press
   Google Scholar
• Marti G. E., Faguet G. B., Bertin P., Agee J. F., Washington G. C., Rest-Ruiz S., Carter P. H., Noguchi P. D. Cell cycle dependent expression of the common chronic lymphocytic leukemia antigen (cCLLa). Cytometry Suppl 1991; 12(5)488B
   Google Scholar
• Rozman C., Monserrat E. Chronic Lymphocytic Leukemia: When and How to Treat. Blut 1989; 59: 467
   PubMedGoogle Scholar
• Rozman C., Monserrat E. Critical factors in new thearapeutic approaches in chronic lymphocytic leukemia (CLL). Nouv. Rev. Fr. Hemalol 1988; 30: 453
   PubMedGoogle Scholar
• French Cooperative Group on Chronic Lymphocytic Leukemia. Comparison of the A, B, C staging and the Rai's staging from a large prospective series (935 patients). Nouv. Rev. Fr. Hemalol. 1988; 30: 363
   PubMedGoogle Scholar
• French Cooperative Group on Chronic Lymphocytic Leukemia. Natural history of stage A-chronic lymphocytic leukemia (CLL). Delineation of patients not requiring early treatment. A study from 309 patients. Blood 1989; 74: 280A, (Chairman: J. L. Binet; Biostatisticians: J. Benichou, C. Chastang, S. Chevret; Secretaries: G. Dighiero, P. Travade)
   Google Scholar
• French Cooperative Group on Lymphocytic Leukemia. Therapy of chronic lymphocytic leukemia patients. Results from the French cooperative trials. Nouv. Rev. Fr. Hemalol 1988; 30: 443
   PubMedGoogle Scholar
• Grever M. R., Kopecky K. J., Coltman C. A., Files J. C., Greenberg B. R., Hutton J. J., Talley R., Von Hon D. D., Balcerzak S. P. Fludarabine monophosphate: a potential useful agent in chronic lymphocytic leukemia. Nouv. Rev. Fr. Hemalol 1988; 30: 457
   PubMedGoogle Scholar
• Keating M. J., Kantarjian H., Talpaz M., Redman J., McCredie K. B. Fludarabine therapy in chronic lymphocytic leukemia (CLL). Nouv. Rev. Fr. Hematol. 1988; 30: 461
   PubMedGoogle Scholar
• Riscoe M. K., Brournes M. C., Fitchen J. H. Purine metabolism as a target for leukemia chemotherapy. Blood Rev. 1989; 3: 162
   PubMed Web of Science ®Google Scholar
• Piro L. D., Carrera C. J., Beutler E., Carson D. A. 2-Chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia. Blood 1988; 72: 1069
   PubMed Web of Science ®Google Scholar
• Oldham R. K.B. The fourth modality of cancer treatment. J. Cell Physiol 1986; 4: 91
   Google Scholar
• Mihich E. Biological response modifiers: Their potential and limitations in cancer therapeutics. Cancer Invest. 1985; 3: 71
   PubMed Web of Science ®Google Scholar
• O'Connell M. J., Oken M. M., Kay N. E., Colgan J. P., Ritts R. E., Itri L. M. Clinical trial of recombinant leukocyte A interferon as initial therapy for favorable histology non-Hodgkin's lymphomas and chronic lymphocytic leukemia. An Eastern Cooperative Oncology Group Pilot Study. J. Clin. Oncol. 1986; 4: 128
   PubMed Web of Science ®Google Scholar
• Talpaz M., Kurzrock R., Kantarjian H., Rosenblum M., Reuben J., Gutterman J. Clinical and laboratory changes induced by alpha interferon in chronic lymphocytic leukemia-A pilot study. Am. J. Hemalol 1987; 24: 341
   PubMed Web of Science ®Google Scholar
• Foon K. A., Schroff R. W., Bunn P. A., Mayer D., Abrams P. G., Fer M., Ochs J., Bottino G. C., Sherwin S. A., Carlo D. J., Herberman R. B., Oldham R. K. Effects of monoclonal antibody therapy in patients with chronic lymphocytic leukemia. Blood 1984; 64: 1085
   PubMed Web of Science ®Google Scholar
• Dillman R. O., Shawler D. L., Sobol R. E., Collins H. A., Beauregard J. C., Wormsley S. B., Royston 1. Murine monoclonal antibody therapy in two patients with chronic lymphocytic leukemia. Blood 1982; 59: 1036
   PubMed Web of Science ®Google Scholar
• Meeker T. C., Lowder J., Maloney D. G., Miller R. A., Thielmans K., Warnke R., Levy R. A clinical trial of anti-idiotype therapy for B cell malignancy. Blood 1985; 65: 1349
   PubMed Web of Science ®Google Scholar
• Vitteta E. S., Fulton R. J., May R. D., Till M., Uhr J. W. Redesigning nature's poisons to create anti-tumor reagents. Science 1987; 238: 1098
   PubMed Web of Science ®Google Scholar
• Hertler A. A., Schlossman D. M., Borowitz M. J., Laurent G., Jansen F. K., Schmidt C., Frankel A. E. A phase 1 study of T101-ricin A chain immunotoxin in refractory chronic lymphocytic leukemia. J. Biol. Response. Mod. 1988; 7: 97
   PubMedGoogle Scholar
• Faguet G. B., Agee J. F. Kinetics of the malignant clone during fludarabine treatment of chronic lymphatic leukemia (CLL). Blood 1989; 74: 75A
   Google Scholar
• Herberman R. B. Biological response modifiers for the therapy of cancer. Ann. Allergy 1985; 54: 376–380
   PubMedGoogle Scholar
• Agee J. F., Wang G., Faguet G. B. In vitro evaluation of a ricin A chain-based immunotoxin directed against the common chronic lymphocytic leukemia antigen (cCLLa): A potential biological agent for in vivo therapy. The FASEBJ 1990; 4: A1498
   Google Scholar
• Faguet G. B., Agee J. F. Deglycosylated ricin A chain-based immunotoxin directed against the common chronic lymphocytic antigen (cCLLa): in vitro specificity and cytotoxic activity. Blood 1990; 76: 1063A
   Google Scholar